Danmark - dansk - SEGES Landbrug & Fødevarer

inter-trade a/s - pirimicarb - vanddispergerbart granulat - 500 g/kg pirimicarb

Danmark - dansk - SEGES Landbrug & Fødevarer

inter-trade a/s - cypermethrin - suspensionskoncentrat - 100 g/l cypermethrin

Danmark - dansk - SEGES Landbrug & Fødevarer

inter-trade a/s - epoxiconazol - suspensionskoncentrat - 125 g/l epoxiconazol

Danmark - dansk - SEGES Landbrug & Fødevarer

basf a/s - epoxiconazol, fenpropimorph - suspoemulsion - 84 g/l epoxiconazol ; 250 g/l fenpropimorph

Danmark - dansk - SEGES Landbrug & Fødevarer

basf a/s - metconazol, epoxiconazol - emulsionskoncentrat - 27,5 g/l metconazol ; 37,5 g/l epoxiconazol

Danmark - dansk - SEGES Landbrug & Fødevarer

inter-trade a/s - chlormequat-chlorid, chlormequat - flydende middel - 720 g/l chlormequat-chlorid ; (~ 559 g/l chlormequat

Danmark - dansk - SEGES Landbrug & Fødevarer

inter-trade a/s - ethephon - flydende middel - 480 g/l ethephon

Danmark - dansk - SEGES Landbrug & Fødevarer

inter-trade a/s - imazalil - flydende middel - 50 g/l imazalil

Den Europæiske Union - dansk - EMA (European Medicines Agency)

viatris limited - clopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for yderligere oplysninger henvises der til afsnit 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrelhydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiske midler - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.